Atlas Trials

Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies

Clinical trial NCT00083525 · COMPLETED

Trial details

NCT number
NCT00083525
Sponsor
Heidelberg Pharma AG
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Advanced Malignancies
Start date
2004-05-01
Enrollment
33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.